Pan-PPAR agonists: emerging therapeutic strategies for metabolic dysfunction-associated steatotic liver disease.
The biological rationale for PPAR modulation in MASLD is delineated, the biological rationale for PPAR modulation in MASLD is critically evaluated, current preclinical and clinical evidence for pan-PPAR agonists is critically evaluated, and emerging strategies for optimizing their development as comprehensive therapeut...